Table 2.
Patient and tumor characteristics at time of GI cancer diagnosis
| Characteristics | Colon |
Stomach |
Pancreas |
Rectum |
Esophagus |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| HL-GI | GI-1 | HL-GI | GI-1 | HL-GI | GI-1 | HL-GI | GI-1 | HL-GI | GI-1 | |
| Number of patients | 105 | 240 459 | 35 | 53 131 | 30 | 62 336 | 21 | 97 256 | 18 | 23 410 |
| Age at GI cancer diagnosis (years) | ||||||||||
| Median | 63 | 71 | 52 | 69 | 61 | 69 | 58 | 67 | 58 | 66 |
| <49 | 20% | 7% | 46% | 10% | 30% | 7% | 24% | 10% | 28% | 9% |
| 50–69 | 44% | 39% | 40% | 42% | 43% | 44% | 52% | 47% | 61% | 55% |
| 70+ | 36% | 54% | 14% | 48% | 27% | 48% | 24% | 43% | 11% | 37% |
| P | <0.0001 | <0.0001* | 0.013* | 0.01* | 0.000587 | |||||
| Gender | ||||||||||
| Male | 54% | 48% | 71% | 63% | 63% | 51% | 76% | 56% | 78% | 76% |
| Female | 46% | 52% | 29% | 37% | 37% | 49% | 29% | 44% | 22% | 24% |
| P | 0.204 | 0.3819 | 1* | 0.1356 | 0.2016 | |||||
| Latency (years) | ||||||||||
| <10 | 30% | NA | 22% | NA | 34% | NA | 62% | NA | 28% | NA |
| 10–20 | 39% | NA | 46% | NA | 30% | NA | 24% | NA | 44% | NA |
| 20–30 | 21% | NA | 31% | NA | 37% | NA | 14% | NA | 28% | NA |
| Cancer stage | ||||||||||
| Localized | 33% | 37% | 23% | 23% | 3% | 12% | 48% | 46% | 22% | 32% |
| Regional | 39% | 40% | 40% | 36% | 43% | 32% | 43% | 37% | 61% | 33% |
| Metastatic | 28% | 23% | 37% | 41% | 53% | 69% | 10% | 18% | 17% | 35% |
| P | 0.4579 | 0.908 | 0.05482* | 0.6805* | 0.1479* | |||||
| Grade | ||||||||||
| I | 11% | 11% | 0% | 5% | 13% | 6% | 0% | 11% | 6% | 6% |
| II | 52% | 50% | 20% | 19% | 30% | 14% | 67% | 52% | 6% | 30% |
| III | 16% | 16% | 49% | 44% | 10% | 17% | 14% | 13% | 67% | 38% |
| IV | 3% | 1% | 11% | 4% | 0% | 2% | 0% | 1% | 6% | 3% |
| Unknown | 17% | 21% | 20% | 27% | 47% | 61% | 19% | 23% | 17% | 23% |
| P | 0.4596*a | 0.1682*a | 0.1018*a | 0.1018*a | 0.02706*a | |||||
| Surgery | ||||||||||
| Yes | 91% | 92% | 30% | 30% | 44% | 44% | 95% | 88% | 30% | 15% |
| No | 9% | 7% | 70% | 70% | 56% | 56% | 5% | 11% | 70% | 80% |
| Unknown | 0% | 1% | 0% | 0% | 0% | 0% | 0% | 1% | 0% | 5% |
| P | 0.5718a | 0.8598a | 0.04173a | 0.04173a | 0.4593a | |||||
| Radiotherapy | ||||||||||
| Yes | 3% | 3% | 29% | 29% | 17% | 17% | 59% | 19% | 29% | 10% |
| No | 96% | 97% | 90% | 90% | 56% | 56% | 81% | 70% | 90% | 18% |
| Unknown | 1% | 0% | 0% | 0% | 0% | 0% | 0% | 1% | 0% | 82% |
| P | 1*a | 0.8238a | 0.3447*a | 0.3447*a | 0.2266a | |||||
P values represent chi-squared test comparing the distribution between HL-GI and GI-1 patients for the GI sites and the indicated variables.
aRepresents chi-squared test omitting patients with unknown variables.
*Represents P values from fisher's exact test.
GI, gastrointestinal; HL-GI, cancer in the gastrointestinal tract after Hodgkin's lymphoma; GI-1, first or only primary cancer in the gastrointestinal tract; NA, not available.